Publication Archives: 2014
-
(2013)
Tavassoly O, Nokhrin S, Dmitriev O Y et al
Cu(II) and dopamine bind to α-Synuclein and cause large conformational changes
FEBS Journal; DOI: 10.1111/febs.12817
-
(2013)
Liu G, Yu J, Ding J et al
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
JCI: The Journal of Clinical Investigation; doi:10.1172/JCI72176..
-
(2013)
Modi G, Voshavar C, Gogoi S et al
Multifunctional D2/D3 Agonist D-520 with High in Vivo Efficacy: Modulator of Toxicity of Alpha-Synuclein Aggregates
ACS Chemical Neuroscience; DOI: 10.1021/cn500084x.
-
(2013)
Tavassoly O, Kakish J, Nokhrin S , et al
The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease
European Journal of Medicinal Chemistry; DOI: 10.1016/j.ejmech.2014.07.090.
-
(2013)
Kellie, J., Higgs, R., Ryder, J. et al
Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
Scientific Reports; doi:10.1038/srep05797
-
(2013)
Shi, Min et al
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Acta Neurolpathol.; doi: 10.1007/s00401-014-1314-y.
-
(2013)
Pchelina, S.N., Nuzhnyib E.P., Emelyanov A.K., et al
Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases
Neuroscience Letters; doi:10.1016/j.neulet.2014.09.041.
-
(2013)
Heinzel S, Gold M, Deuschle C et al
Naturally Occurring Alpha-Synuclein Autoantibodies in Parkinson’s Disease: Sources of (Error) Variance in Biomarker Assays
PLoS One; https://doi.org/10.1371/journal.pone.0114566.
-
(2013)
Scott Miners, Ruth Renfrew, Marta Swirski, Seth Love
Accumulation of α-synuclein in dementia with Lewy bodies is associated with decline in the α-synuclein-degrading enzymes kallikrein-6 and calpain-1
Acta Neuropathol Commun.; doi: 10.1186/s40478-014-0164-0
